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Abstract: 
Background and aim: This study aimed to predict methylation status of the O-6 
methyl guanine-DNA methyl transferase (MGMT) gene promoter status by using 
MRI radiomics features, as well as univariate and multivariate analysis. 
 
Material and Methods: Eighty-two patients who had a MGMT methylation status 
were include in this study. Tumor were manually segmented in the four regions of 
MR images, a) whole tumor, b) active/enhanced region, c) necrotic regions and d) 
edema regions (E). About seven thousand radiomics features were extracted for each 
patient. Feature selection and classifier were used to predict MGMT status through 
different machine learning algorithms. The area under the curve (AUC) of receiver 
operating characteristic (ROC) curve was used for model evaluations.  
 
Results: Regarding univariate analysis, the Inverse Variance feature from gray level 
co-occurrence matrix (GLCM) in Whole Tumor segment with 4.5 mm Sigma of 
Laplacian of Gaussian filter with AUC: 0.71 (p-value: 0.002) was found to be the 
best predictor.  For multivariate analysis, the decision tree classifier with Select from 
Model feature selector and LOG filter in Edema region had the highest performance 
(AUC:  0.78), followed by Ada Boost classifier with Select from Model feature 
selector and LOG filter in Edema region (AUC:  0.74). 
 
Conclusion: This study showed that radiomics using machine learning algorithms 
is a feasible, noninvasive approach to predict MGMT methylation status in GBM 
cancer patients 
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Introduction: 
Glioblastoma multiforms (GBM) are one of the most aggressive malignant brain tumors with an 
occurrence rate of 2 to 3 cases per 100,000 individuals (1). Post diagnosis, these patients have a 
median survival time of 15 months, with less than 5% of patients having a 5-year survival time 
(2). This poor prognosis results from the intra-tumor genetic heterogeneous pattern of GBM (3).  
Currently, temozolomide (TMZ) is the forefront in therapy for GBM patients. This treatment 
causes alkylation at the O-6 guanine of DNA, subsequently inducing cytotoxic effects and death 
in cancer cells (4). Studies show that the methylation status of the O-6 methylguanine-DNA 
methyltransferase (MGMT) gene promoter could be a predictor for the efficacy of TMZ treatment 
(5) MGMT is a vital gene which encodes a DNA repair protein (6). Tumor cells with MGMT 
expression show resistance to TMZ, while tumor cells without MGMT expression are more 
sensitive to TMZ. Demethylation of the DNA O-6 guanine by MGMT prohibits the DNA 
degradation induced by TMZ. GBM patients with MGMT promoter silencing show a higher 
response to TMZ. Several studies have shown that MGMT promoter methylation is associated 
with longer survival (7-9). 
In GBM patients without surgical resection indications, it has been shown that medical imaging 
could help understand the tumor pathology (10). Clinical studies have indicated that magnetic 
resonance imaging (MRI) sequences such as T1, T1-contrast, T2, and FLAIR have a feasible role 
for the prognosis, diagnosis, and treatment plan for GBM (11). Furthermore , further research 
studies have introduced radiomics as a novel field which can also be used as a powerful prognostic 
tool (12-14). In combination with MRI sequences, these tools can have a major impact on GBM 
patient management through higher stratification (15). 
  
Radiomics is an advanced image processing technique which extracts a large number of 
quantitative features with standard and special algorithms. These features are then correlated with 
clinical outcomes. The features are shape, intensity, and texture based. The aforementioned 
features are used during clinical decision making for patient diagnosis, prognosis, and therapy 
response prediction/assessment (16-18). An extension of this field is radiogenomics, where 
radiomics features are correlated with genomics parameters (19-21).  
Tissue sampling with surgical resection is the gold-standard for the determination of MGMT 
promoter methylation status. However, this method has limitations such as GBM heterogeneity, a 
large volume of tissue specimens, and the cost of testing in clinics where it is not routine (22, 23). 
Recently, radiomics features have been used as imaging biomarkers in MGMT methylation status 
prediction (24, 25). These quantitative features are reported to simplify the optimum tissue 
specimen at surgery (26). Multiple studies have explored the efficacy of using these quantitative 
features in MGMT methylation status prediction. A study by Iliadis et al. (27) showed that necrosis 
volume is inversely associated with MGMT protein–positive tumor cells . Furthermore, a study by 
Levner et al used neural networks as a classifier with S-transform texture features acquired from 
MRI sequences (T2-w, FLAIR, and T1-w CE) and achieved over 87% accuracy for the prediction 
of MGMT methylation status (28). Additionally, a study by Eoli et al reported that contrast 
enhanced regions of tumors are correlated with an unmethylated status (29). Moreover, a study by 
Drabycz et al evaluated Visually Accessible Rembrandt Images (VASARI) and automatic texture 
features for the prediction of MGMT methylation status. Their results revealed that incorporating 
VASARI with texture features improves the predictive power of MGMT methylation status (30). 
In another study, Moon et al. (24) found that there are several correlations between MGMT 
methylation status and features extracted from computed tomography (CT) and T2∗ dynamic 
  
susceptibility, contrast enhanced perfusion-weighted imaging, and diffusion tensor imaging MRI 
features.   
This present study aims to predict MGMT status by using T2W and T1W MRI radiomics features, 
along with univariate and multivariate analysis. 
 
 
 
 
 
 
 
 
  
Material and Methods: 
Figure 1 shows the process flow followed in the paper. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.Illustrates the process flow followed in the paper. 
  
-                     GBM Patient Dataset 
In this study, a total of 122 patients with pathologically confirmed GBM who had two MR images 
sequences (T2 fluid attenuation inversion recovery (FLAIR) and T1-W CE) were included. All 
images were downloaded from the cancer imaging archive (TCIA) (31, 32). Clinical data from 
TCGA (33) and Bady et al. (34) were used to determine the MGMT methylation status using probe 
cg12434587 and cg12981137 values on HumanMethylation27 and HumanMethylation450 
databases. Lastly, 82 patients who had a MGMT methylation status were kept in this study while 
the remainder of the data was excluded. Table 1 outlines the clinical characteristics of the patients 
included in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Clinical characteristics of MGMT status dataset 
 
 
 
 
Characteristic No.(%) 
Patient N=82 
Gender  
    Male 46 (56.1%) 
    Female 36 (43.9%) 
Age, Y 57.4 ± 13.9 
MGMT Status  
    Methylation 45 (54.9%) 
    Unmethylation 37 (45.1%) 
Karnofsky performance score  
    <70 51 (62.2%) 
    >70 23 (28%) 
    Not Available 8 (9.8%) 
  
-                     Segmentation 
Tumor were manually segmented with a 3D slicer in the following four regions a) whole tumor 
(WT), b) active/enhanced tumor (A), c) necrotic regions (N) in T1W CE imaging and d) edema 
regions (E) in T2 FLAIR imaging. All segmentations were verified by an expert radiologist. 
-                     Feature extraction 
Before feature extraction, the images were pre-processed. For pre-processing, images were 
discretized and resampled to 16, 32, 64, 128, 256 gray level bin sizes. Additionally, wavelet 
(WAV) with different decompositions (HHH, HHL, HLH, HLL, LHH, LHL, LLH and LLL) and 
Laplacian of Gaussian (LOG) filters with different sigma values (0.5 to 5 with step 0.5) were 
applied. Feature extraction included three feature sets: shape based, first order, and textures. 
Thirteen shape features were extracted for each segment along with A/WT ratios, N/WT ratios, 
and WT/E ratios for the features. Texture sets were Gray Level Co-occurrence Matrix (GLCM), 
Gray Level Run Length Matrix (GLRLM), Gray Level Dependence Matrix (GLDM), Gray Level 
Size Zone Matrix (GLSZM), and Neighboring Gray Tone Difference Matrix (NGTDM) (Table 1s 
in supplemental data). About 7047 features were extracted for each patient, and 41 image sets were 
prepared for model evaluations (Table 2s in supplemental data).
  
Supplemental Table 1. Radiomics Features 
 
 
 
 
 
 
 
 
 
 
 
 
 
 First Order Statistics (FOS)  Gray Level Co-occurrence Matrix (GLCM)  Gray Level Run Length Matrix (GLRLM) 
  
 Energy 
 Total Energy 
 Entropy 
 Minimum 
 10th percentile 
 90th percentile 
 Maximum 
 Mean 
 Median 
 Interquartile Range 
 Range 
 Mean Absolute Deviation (MAD) 
 Robust Mean Absolute Deviation (rMAD) 
 Root Mean Squared (RMS) 
 Standard Deviation 
 Skewness 
 Kurtosis 
 Variance 
 19. Uniformity 
  
 Autocorrelation 
 Joint Average 
 Cluster Prominence 
 Cluster Shade 
 Cluster Tendency 
 Contrast 
 Correlation 
 Difference Average 
 Difference Entropy 
 Difference Variance 
 Joint Energy 
 Joint Entropy 
 Informal Measure of Correlation (IMC) 1 
 Informal Measure of Correlation (IMC) 2 
 Inverse Difference Moment (IDM) 
 Inverse Difference Moment Normalized (IDMN) 
 Inverse Difference (ID) 
 Inverse Difference Normalized (IDN) 
 Inverse Variance 
 Maximum Probability 
 Sum Average 
 Sum Entropy 
 23. Sum of Squares 
  
 Short Run Emphasis (SRE) 
 Long Run Emphasis (LRE) 
 Gray Level Non-Uniformity (GLN) 
 Gray Level Non-Uniformity Normalized (GLNN) 
 Run Length Non-Uniformity (RLN) 
 Run Length Non-Uniformity Normalized (RLNN) 
 Run Percentage (RP) 
 Gray Level Variance (GLV) 
 Run Variance (RV) 
 Run Entropy (RE) 
 Low Gray Level Run Emphasis (LGLRE) 
 High Gray Level Run Emphasis (HGLRE) 
 Short Run Low Gray Level Emphasis (SRLGLE) 
 Short Run High Gray Level Emphasis (SRHGLE) 
 Long Run Low Gray Level Emphasis (LRLGLE) 
 16. Long Run High Gray Level Emphasis (LRHGLE) 
 Gray Level Dependence Matrix (GLDM) 
  
 Small Dependence Emphasis (SDE) 
 Large Dependence Emphasis (LDE) 
 Gray Level Non-Uniformity (GLN) 
 Dependence Non-Uniformity (DN) 
 Dependence Non-Uniformity Normalized (DNN) 
 Gray Level Variance (GLV) 
 Dependence Variance (DV) 
 Dependence Entropy (DE) 
 Low Gray Level Emphasis (LGLE) 
 High Gray Level Emphasis (HGLE) 
 Small Dependence Low Gray Level Emphasis (SDLGLE) 
 Small Dependence High Gray Level Emphasis (SDHGLE) 
 Large Dependence Low Gray Level Emphasis (LDLGLE) 
 14. Large Dependence High Gray Level Emphasis (LDHGLE) 
 Shape Features  Gray Level Size Zone Matrix (GLSZM) 
  
 Volume 
 Surface Area 
 Surface Area to Volume ratio 
 Sphericity 
 Compactness 1 
 Compactness 2 
 Spherical Disproportion 
 Maximum 3D diameter 
 Maximum 2D diameter (Slice) 
 Maximum 2D diameter (Column) 
 Maximum 2D diameter (Row) 
 Major Axis 
 Minor Axis 
 Least Axis 
 Elongation 
 Flatness 
 A/T volume ratio 
 N/T volume ratio 
 T/E volume ratio 
  
 Small Area Emphasis (SAE) 
 Large Area Emphasis (LAE) 
 Gray Level Non-Uniformity (GLN) 
 Gray Level Non-Uniformity Normalized (GLNN) 
 Size-Zone Non-Uniformity (SZN) 
 Size-Zone Non-Uniformity Normalized (SZNN) 
 Zone Percentage (ZP) 
 Gray Level Variance (GLV) 
 Zone Variance (ZV) 
 Zone Entropy (ZE) 
 Low Gray Level Zone Emphasis (LGLZE) 
 High Gray Level Zone Emphasis (HGLZE) 
 Small Area Low Gray Level Emphasis (SALGLE) 
 Small Area High Gray Level Emphasis (SAHGLE) 
 Large Area Low Gray Level Emphasis (LALGLE) 
 16. Large Area High Gray Level Emphasis (LAHGLE) 
 Neighboring Gray Tone Difference Matrix (NGTDM) 
  
 1-Coarseness 
 2-Contrast 
 3-Busyness 
 4-Complexity 
 5- Strength 
  
Supplemental Table 2. Image data sets 
 
  
FILTER SEGMENT NO. OF 
FEATURES 
NO. OF IMAGE 
SETS 
SHAPE ANTE 55 1 
BIN 16 A, N, T, E, 92 4 
BIN 32 A, N, T, E, 92 4 
BIN 64 A, N, T, E, ANTE 
SHAPE+ANTE 
92 
368 
423 
4 
1 
1 
BIN 128 A, N, T, E, 92 4 
BIN 256 A, N, T, E, 92 4 
LOG A, N, T, E, ANTE 
SHAPE+ANTE 
920 
3680 
3735 
4 
1 
1 
WAV A, N, T, E, ANTE 
SHAPE+ANTE 
736 
2944 
2999 
4 
1 
1 
BIN 64+ LOG+WAV A, N, T, E, ANTE 
SHAPE+ANTE 
1748 
6992 
7047 
4 
1 
1 
SUM  7047 41 
  
-                     Feature selection 
Seven different feature selections methods were used in the framework and performances were 
compared (see Table 2). 
-                     Classifiers 
Twelve Classifiers were implemented and compared (Table 2).  The details of each classifier are 
provided in Table 3s (supplementary). 
Table 2. Feature selection and Classification methods 
 
 
 
-                     Evaluation 
For univariate analysis, each feature value was normalized to obtain Z-scores, followed by student 
t-test students for comparison. A p-value of <0.05 was used as a criterion for statistically 
significant results. Area under the curve (AUC) of the receiver operating characteristic (ROC) 
curve was used to determine which feature could predict MGMT methylation status. Statistical 
analysis for this portion was performed in R 3.5.1 (using ‘pROC’ and ‘stats’ packages). 
For multivariate analysis, an in-house developed python framework was used. A 10 fold cross-
validation (CV) was applied for model evaluation. Furthermore, the AUC of ROC curves were 
also used for model evaluations. Heat-maps and boxplots were constructed to compare different 
developed models. Lastly, the cross combinations of feature selections and classification methods 
were depicted as a heat-map (using mean AUC values in cross validation). 
 
 Feature Selection Methods Abbreviation  Classification Methods Abbreviation 
1 Select K Best  KB 1 Adaptive Boost  AB 
2 Select K Best & Mutual Info 
Regression  
KB-MIR 2 Bagging BAG 
3 Select From Model  SM 3 Naive Bayes NB 
4 Select Percentile  SP 4 Decision Tree  DT 
5 Variance Threshold  VT 5 Gaussian Naive Bayes GNB 
6 Variance Threshold & Select From 
Model  
VT-SM 6 K-Nearest Neighbors KNN 
7 Variance Threshold & Select K Best & 
Mutual Info Regression  
VT-KB-MIR 7 Logistic Regression LREG 
   8 Multilayer Perceptron MLP 
   9 Quadratic Discriminant 
Analysis 
QDA 
   10 Random Forest  RF 
   11 Stochastic Gradient 
Descent 
SGD 
   12 Support Vector Machine  SVM 
  
Results: 
Table 3 summarizes univariate analyses sorted according to AUC values in top 20 features with 
different filters and segments. The best predictor of MGMT methylation status was the Inverse 
Variance feature of GLCM (GLCM_IV) in a Whole Tumor segment with 4.5mm Sigma of 
Laplacian of Gaussian filter (LOG_4.5S) (AUC: 0.71, p-value: 0.002). Table 4 summarizes the 
univariate analyses of shape features. Sphericity in the active region (AUC: 0.62, p-value: 0.06) 
and Elongation and Flatness in edema regions (AUC: 0.62, p-value: 0.08) had better performances 
in the prediction of MGMT methylation status. 
Table 3. Top univariate analysis sorted by AUC 
Features Filter Region AUC p-value 
GLCM_IV LOG_4.5S Whole Tumor 0.71 0.003 
GLCM_IV LOG_5.0S Whole Tumor 0.70 0.003 
GLCM_IV LOG_4.0S Whole Tumor 0.69 0.008 
NGTDM_Strength LOG_2.0S Whole Tumor 0.68 0.050 
GLCM_IV LOG_4.5S Active 0.68 0.024 
FO_Skewness LOG_4.5S Edema 0.68 0.010 
GLCM_IV LOG_5.0S Active 0.68 0.014 
GLDM_DV W_LLL Necrosis 0.68 0.050 
GLSZM_LALGLE LOG_5.0S Necrosis 0.68 0.063 
NGTDM_Strength LOG_5.0S Necrosis 0.68 0.410 
GLCM_IV W_LLL Necrosis 0.68 0.004 
GLDM_LDE W_LLL Necrosis 0.67 0.022 
GLCM_IDM W_LLL Necrosis 0.67 0.010 
FO_Kurtosis LOG_2.5S Edema 0.67 0.002 
NGTDM_Complexity W_LLL Necrosis 0.67 0.213 
GLCM_Id W_LLL Necrosis 0.67 0.012 
NGTDM_Strength LOG_2.0S Necrosis 0.67 0.055 
NGTDM_Strength LOG_2.5S Necrosis 0.67 0.273 
NGTDM_Complexity LOG_2.0S Whole Tumor 0.67 0.148 
FO_Kurtosis LOG_2.0S Edema 0.67 0.007 
 
The Decision Tree classifier with Select from Model feature selector (DT_SFM) in LOG filter in 
Edema region (E) features had the highest performance (AUC:  0.78). The Ada-Boost classifier 
with Select from Model feature selector in LOG filter (AB_SFM) in Edema regions (E) features 
(AUC:  0.74) follows in highest performance (Figure 4s from the supplementary data). 
Figure 2 summarizes the results regarding MGMT mutation status prediction based on feature 
selection and image sets. According to these results, the feature selection performance had a range 
of 0.52 to 0.61. Additionally, a combination of the Select from Model feature selector (SFM) + the 
LOG filter in Edema region (E) had the highest performance (AUC: 0.61), followed by a 
combination of the Variance Threshold and the Select from Model feature selector (VT_SFM) + 
LOG filter in Edema region (E) (AUC: 0.6). 
  
Figure 3 displays the results regarding MGMT mutation status prediction based on feature 
classification and image sets. According to these results, classification performance had a range of 
0.50 to 0.68. Support Vector Machine classifier (SVM) + combination of Bin 64, LOG and 
Wavelet (BLW) filters in Necrosis region (N) had the highest performance (AUC: 0.68). This is 
followed by Ada-Boost classifier (AB) + Bin 16 in Active region (A) (AUC: 0.68), Decision Tree 
classifier (DT) + Bin 256 in Edema region (E) (AUC: 0.66), and Random Forest classifier (RF) + 
Bin 256 Edema region (E) (AUC: 0.65).  
  
 
 
 Figure 2. Heatmap depicting predictive performance (mean AUC) of image sets (rows) and 
feature selection methods (columns) in prediction of MGMT methylation status. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Heatmap depicting predictive performance (mean AUC) of image sets (rows) and 
classifier methods (columns) in prediction of MGMT methylation status. 
  
 
Figures 4-a and 1s (from the supplementary data) show the results for the prediction of MGMT 
mutation status in Active tumor regions. It is seen that model performance (mean AUC) had a wide 
range of 0.50 to 0.68 and Bin 256 had both the highest mean (AUC: 0.55) and the highest predictive 
performance (AUC: 0.68). Figures 4-b, and 2s (from the supplementary data) show the results for 
the prediction of MGMT mutation status in Necrosis tumor regions. Notable results include that 
model performance (mean AUC) had a wide range of 0.50 to 0.68, and a combination of Bin 64, 
LOG, and Wavelet filters (BLW) images had both the highest mean (AUC: 0.55) and the highest 
predictive performance (AUC: 0.68). 
Figures 4-c and 3s (from the supplementary data) show the results for the prediction of MGMT 
mutation status in Whole Tumor regions. It should be noted that model performance (mean AUC) 
had a wide range of 0.50 to 0.69, image set Bin 32 had the highest mean (AUC: 0.55), and image 
set Bin 256 had the highest predictive performance (AUC: 0.69). Figures 4-d and 4s (from the 
supplementary data) show the results for the prediction of MGMT mutation status in Edema 
regions. It is seen that model performance (mean AUC) had a wide range of 0.50 to 0.78, and 
image set LOG filter had both the highest mean (AUC: 0.57) and the highest predictive 
performance (AUC: 0.78). 
Figures 5-a and 5s (from the supplementary data) show the results for the prediction of MGMT 
mutation status in a combination of all tumor regions. Results show that model performance (mean 
AUC) had a wide range from 0.50 to 0.68, image set Bin 64 had the highest mean (AUC: 0.56), 
and image set LOG filter and combination with shape features had the highest predictive 
performance (AUC: 0.68). Figure 5-b shows the results regarding MGMT mutation status 
prediction based on feature selection. A combination of the Variance Threshold and the Select 
from Model feature selector (VT_SFM) had higher mean predictive performances than other 
feature selectors (AUC: 0.56). Figure 5-c shows the results regarding MGMT mutation status 
prediction based on Classifiers. The Ada-Boost classifier (AB) had a higher mean predictive 
performance than any other Classifier (AUC: 0.59). 
  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. (a) Boxplot show predictive performance (AUC) (y-axis) of Active tumor region 
image sets (x-axis). (b) Boxplot show predictive performance (AUC) (y-axis) of Necrosis tumor 
region image sets (x-axis). (c) Boxplot show predictive performance (AUC) (y-axis) of Whole 
Tumor region image sets (x-axis). (d) Boxplot show predictive performance (AUC) (y-axis) 
of Edema tumor region image sets (x-axis). 
 
Figure 5. (a) Boxplot show predictive performance (AUC) (y-axis) of combination of all tumor 
regions image sets (x-axis). (b) Boxplot show predictive performance (AUC) (y-axis) of feature 
selection methods (x-axis). (c) Boxplot show predictive performance (AUC) (y-axis) of classifier 
methods (x-axis). 
  
 
 
             
             
             
             
             
             
             
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1. Heatmap depicting the predictive performance (AUC) of feature 
selection/classification methods (rows) and Active tumor region image sets (columns) in 
prediction MGMT methylation status.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplemental Figure 2. Heatmap depicting the predictive performance (AUC) of feature 
selection/classification methods (rows) and Necrosis tumor region image sets (columns) in 
prediction MGMT methylation status. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 3. Heatmap depicting the predictive performance (AUC) of feature 
selection/classification methods (rows) and Whole Tumor region image sets (columns) in 
prediction MGMT methylation status. 
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Supplemental Figure 4. Heatmap depicting the predictive performance (AUC) of feature 
selection/classification methods (rows) and Edema region image sets (columns) in prediction 
MGMT methylation status. 
  
 
 
 
 
 
 
 
 
  
Supplemental Figure 5. Heatmap depicting the predictive performance (AUC) of feature 
selection/classification methods (rows) and combination of all tumor regions image sets 
(columns) in prediction MGMT methylation status. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplemental Figure 6. Heatmap depicting the predictive performance (AUC) of feature 
selection/classification methods (rows) and image sets (columns) in prediction MGMT 
methylation status 
  
Discussion: 
This study elaborated on an extensive radiomics technique that combines univariate and 
multivariate analysis with statistical and machine learning methods. This was accomplished by 
using a large number of features extracted from T1-W CE and T2-FLAIR images taken of 82 GBM 
patients to predict their MGMT mutation status. 
This study showed that GLCM_IV extracted from all segmented regions is an appropriate marker 
in predicting MGMT methylation status. Also, it was found that the Decision Tree classifier with 
Select from Model feature selector (DT_SFM) in LOG filter preprocessed in Edema region (E) 
features had the highest performance (best model, AUC:  0.78). From the classifier and feature 
selections, AB and VT+SFM had higher mean performances, respectively.  In the combinations 
of 4 segments among 8 image sets, Bin 64 had the highest mean and the LOG filter + shape features 
image set had the highest predictive performance. 
In a study by Li et al. (35), they tested the ability of univariate and multivariate analyses in the 
prediction of MGMT methylation status. Their study developed two multivariate radiomics models 
to predict MGMT methylation status in GBM cancer patients. They reported that there lacks a 
statistically significant difference in shape features between methylated and unmethylated MGMT 
tumors. Several studies have shown that there are no statistically significant differences in shape 
features between tumors with methylated versus unmethylated MGMT (24, 29, 30, 36, 37). Similar 
to this current study, the aforementioned studies found features that are correlated with parameters 
to MGMT methylation and could partake in model prediction. The results from this current study 
indicate that three shape features (Sphericity in active region, Elongation and Flatness in edema 
region) have AUC > 0.6 (presented at Table 4). Additionally, figure 5-a shows that combination 
shape features with LOG filters could improve prediction. 
Regarding classification algorithms used to predict MGMT methylation status, Korfiatis et al. (26) 
applied a Support Vector Machine (SVM) and Random Forest (RF) classifier on GLCM and 
GLRLM features extracted from T1w-CE and T2w images in Enhanced region. Their results 
showed that the RF classifier had AUC: 0.75 from T1w-CE and AUC: 0.84 from T2w. The SVM 
classifier had an AUC: 0.76 from T1w-CE and AUC: 0.85 from T2w. This developed model was 
found to be a high performance predictive model. Performance of our model in the enhanced region 
is lower than the one found in this study (Figure 1s). However, Korfiatis et al. did not extract 
features from other regions, and the extracted features were limited.  Our results show that SVM 
  
classifier in combination with all features (BWL imageset) in the necrotic region had the best 
performance (AUC: 0.68). 
Xi et al. (25) reported that combinations of sequences improved prediction performance as 
opposed to singular sequences. They found that T1-WI, T2-WI, and enhanced T1-WI radiomics 
features could predict MGMT promoter methylation with an accuracy of 86.59% in the training 
cohort and 80% in the validation cohort. This study extracted features from whole tumors, used 
SVM for classification, and LASSO for feature selection. Our results show that Bin 64 and LOG 
filter + shape features with combinations of four segments in T1w-CE and FLAIR has the best 
performance. 
Furthermore, Wei et al. (38) reported that ADC values are correlated with MGMT methylation 
status. However, they also found that T1-W CE and T2 FLAIR sequences had better performances 
than ADC. Regarding the DWI, the extracted ADC value was found to be a predictor for MGMT 
promoter methylation status with a sensitivity of 84% and a specificity of 91%. Fusion radiomics 
signature model had the best performance. Our model performed well in the necrotic region when 
combining Bin, LOG, and WAV (BLW) filters. 
In this study, multiregional segmentation was used for feature extraction in two MR sequences 
(Figure 1). Regions were also combined to investigate which ones have more prediction power 
(Figure 5-a). Additionally, the impact of MR image pre-processing and combining regions with 
differing MLs on the prediction of tumor MGMT mutation status was evaluated. However, this 
field lacks a comprehensive guideline for the optimal usage of robots features (39-41), classifiers 
(14). Therefore, this study attempted to determine the best classifier and feature selector for such 
investigations. Lastly, the impact of pre-processing MR images on MGMT methylation status 
determination was evaluated. The main limitation of this study was the size of the dataset. To 
overcome this limitation, models were validated using 10-fold cross-validation to reduce the 
sensitivity of the results to input data, as well as increase reliability. Future studies should use 
larger datasets that contain external validation sets. 
 
 
 
 
 
  
Conclusion 
This study showed that radiomics using machine learning algorithms is a feasible, noninvasive 
approach to predict MGMT methylation status in GBM cancer patients. Also, some radiomics 
could predict the issue alone or in combination with other features. This is important because it 
could narrow down the treatment options for patients and increase the safety and efficacy of the 
procedures.  
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